


Facts & Figures




100% focus on our core expertise:

Pharma drug containment and delivery solutions

16

state-of-the-art production facilities

in **14** countries, including all major pharma hubs



Global Footprint



€957 million revenues

(+12% at constant currencies)

€258 million EBITDA

Margin: 26.9%



>1,000

patents and designs developed

>120

employees

active in R&D collaborating with an exclusive network of partners

On average, **more than 25,000 injections per minute** are provided to patients worldwide through a SCHOTT Pharma product.

>12

billion products delivered every year

Glass syringes



Polymer syringes




Cartridges



Vials



Ampoules



Broad ready-to-use portfolio

Market & Customers

The top 30 global pharma companies use SCHOTT Pharma's solutions.

>1,800

customers worldwide



Big pharma innovators



Leading CDMOs



Biotech & start-ups

Growth opportunities from structural trends

mRNA therapies

New drug categories require deep-cold storage (-100°C)



SCHOTT Pharma currently offers the only prefillable syringes for these applications¹

GLP-1 drugs

Increasing demand to treat type-2 diabetes, obesity



SCHOTT Pharma has long-term contracts with the leading GLP-1 players

Homecare solutions

Enabling patients to inject drugs at home, reducing healthcare cost



SCHOTT Pharma contributes to fully integrated systems from device manufacturers

Manufacturing transformation

Smaller patient populations require more flexible filling lines



SCHOTT Pharma offers pre-sterilized, ready-to-use products for utmost flexibility

Subcutaneous injections

Subcutaneous large-volume injections of biologics are more patient-friendly



SCHOTT Pharma's cartridges and syringes feature precise geometry to ensure accurate dosing and reducing injection forces

Antibody-drug conjugates (ADCs)

Innovative ADC therapies need to be lyophilized to ensure drug efficacy



SCHOTT Pharma offers specialty vials that fully eliminate fogging thanks to a hydrophobic inner coating

¹No competitor disclosed a product with mentioned specifications so far

ESG Responsibility



↓ **60%**

reduced CO₂
emissions
since 2019¹

Already using
→ **100%**
green electricity
worldwide


~4,700
employees from over
60
nationalities

**>40% female
employees**

~24%
of leadership positions
held by women



Ownership



Executive Board



**Andreas Reisse,
CEO**

- Over 35 years of experience
- Heading SCHOTT's pharma business since 2010
- Previously headed SCHOTT's Tubing business unit
- Master Degree in Industrial Engineering



**Dr. Almuth Steinkühler,
CFO**

- Over 15 years of experience
- Leading the finance organization since 2022
- Previous management roles with thyssenkrupp and Continental
- PhD in Management Accounting

¹ Scope 1 & 2; Defined as corporate CO₂ footprint of SCHOTT Pharma divided by number of good pieces sold (as of FY 2022)

SCHOTT Pharma's Governance

KGaA (Kommanditgesellschaft auf Aktien) is a listed partnership limited by shares with three **corporate bodies**:

- **general partner** (Komplementär)
- **supervisory board** (Aufsichtsrat)
- **general shareholders' meeting** (Hauptversammlung)

As a **popular legal form** for companies originating from families or foundations, there are many **established KGaA** in Germany.

Supervisory Board

Shareholder representatives



Chairman
Peter Goldschmidt,
CEO
Stada AG



Deputy Chairman
Dr. Wolfram Carius,
Executive Vice President
Bayer AG



Eva Kienle,
CFO
KWS Saat SE & Co. KGaA



Ann-Kristin Erkens,
CFO
SIG Group AG

Employee representatives



Mario Just,
SCHOTT Pharma



Christine Wening,
SCHOTT Pharma

Press contact

Lea Kaiser

lea.kaiser@schott.com

+49 (0) 151/68 91 71 95

Joana Kornblum

joana.kornblum@schott.com

+49 (0) 151/29 22 35 52